✨ Your Portfolio is fetched and updated from zerodha.
Micro Asset Management

Amerise Biosciences Ltd.

AMERISE

Market Cap
₹6 Cr.
P/E
0.00

Amerise Biosciences Ltd.

  • Amerise Biosciences
  • KLG Capital Services
  • Aravali Sec. & Fin
FAQs on Amerise Biosciences Ltd. Shareprice

Amerise Biosciences has given lower returns compared to its competitors.
Amerise Biosciences has grown at ~-18.7% over the last 10yrs while peers have grown at a median rate of -3.3%

Amerise Biosciences is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA.
Latest PE of Amerise Biosciences is 0.0, while 3 year average PE is -0.23.
Also latest EV/EBITDA of Amerise Biosciences is 0.0 while 3yr average is 0.06.

View FAQ's On Business
Growth Table
  • Amerise Biosciences Ltd.
  • KLG Capital Services
  • Aravali Sec. & Fin
Balance Sheet
  • Amerise Biosciences Ltd.
  • KLG Capital Services
  • Aravali Sec. & Fin
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Amerise Biosciences Ltd.
  • KLG Capital Services
  • Aravali Sec. & Fin
Cash Flow
  • Amerise Biosciences Ltd.
  • KLG Capital Services
  • Aravali Sec. & Fin
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Amerise Biosciences Ltd.
  • KLG Capital Services
  • Aravali Sec. & Fin
Quarterly Results
  • Amerise Biosciences Ltd.
  • KLG Capital Services
  • Aravali Sec. & Fin
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Rhapson method.
Learn how to use Reverse DCF
FAQs on Amerise Biosciences Ltd. Financials

Amerise Biosciences balance sheet is weak and might have solvency issues

Yes, The debt of Amerise Biosciences is increasing.
Latest debt of Amerise Biosciences is -₹0.02 Crs as of Sep-24.
This is greater than Mar-24 when it was -₹0.03 Crs.

No, profit is decreasing.
The profit of Amerise Biosciences is -₹0.15 Crs for Mar 2024, -₹0.12 Crs for Mar 2023 and ₹0.55 Crs for Mar 2022

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Amerise Biosciences latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Cash & Short Term Investments, Capital Work in Progress, Inventory, Accounts Receivable, Short Term Loans & Advances

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech